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Objectives The purpose of this study was to assess trends in endothelial coverage and recovery among leading polymer-
based drug-eluting stents (DES).
Background Autopsy studies of human U.S. Food and Drug Administration (FDA)–approved DES implanted coronary arteries
suggest that complications of late stent thrombosis are associated with incomplete endothelial coverage of
struts.
Methods Rabbits received sirolimus-eluting stents (SES), paclitaxel-eluting stents (PES), zotarolimus-eluting stents (ZES),
and everolimus-eluting stents (EES) for 14 or 28 days along with MULTI-LINK (ML) Vision control stents. Endothe-
lial coverage above and between struts was measured by morphometric analysis of images acquired through en
face scanning electron microscopy. Dual fluorescent immunolabeling was performed for platelet-endothelial cell
adhesion molecule (PECAM)-1 and thrombomodulin (TM), factors involved in cell-to-cell contact and thromboge-
nicity, respectively. In a separate analysis, the endothelial mitogen, vascular endothelial growth factor (VEGF),
was also assessed.
Results Varying rates of endothelialization among comparator DES were most notable at 14 days, where coverage above
struts remained poor in SES, PES, and ZES (30%) relative to EES and ML Vision controls (70%), whereas no
significant differences were observed at 28 days. Select DES with poor endothelialization showed a further re-
duced expression of PECAM-1. All DES showed an absence or weak expression of the antithrombotic cofactor
TM. Incomplete endothelialization in select DES was further associated with increased VEGF secretion and mes-
senger ribonucleic acid levels at 14 days, providing evidence of a transitional healing surface.
Conclusions The present study marks the first comparator analysis of endothelial coverage in leading polymeric DES, sup-
porting disparities in arterial healing based on endothelial regrowth and recovery, favoring newer designs over
the current generation of FDA-approved stents. (J Am Coll Cardiol 2008;52:333–42) © 2008 by the American
College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.04.030u
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Jncomplete endothelialization of strut surfaces is a recog-
ized pathologic substrate for late stent thrombosis, an
nfrequent but life-threatening complication of the current
.S. Food and Drug Administration (FDA)–approved
rug-eluting stents (DES) (1–3). Although the underly-
ng mechanisms of late stent thrombosis are poorly
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ent for the maintenance of long-term luminal patency
ecause these cells provide critical structural and anti-
hrombotic functions.
Short of large randomized clinical trials statistically pow-
red for late thrombotic endpoints or through indirect
ethods for assessing endothelial dysfunction such as nitric
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mans (4,5), comparative preclin-
ical histological studies remain
the most effective means of eval-
uating healing of vascular stent
implants. Although arterial re-
pair after stent placement in an-
imals occurs more rapidly than in
humans, animal models still re-
tain predictive value because the
sequence of biological responses
are remarkably similar to humans
(6). The interpretation of animal
data is, however, highly contin-
gent on the timeline after stent
placement. Although examina-
tion of DES implants in swine or
rabbits is often done at 28 days, it
is unclear whether an earlier time
point may reveal more about the
healing characteristics of differ-
ent devices because 28 days is
hought to be equivalent to 12-month coronary stent
mplants in humans (6,7).
Disparities in the degree of arterial healing among species
s equally notable for rates of re-endothelialization after
ascular injury (8,9), in which differences in shear stress,
nderlying atherosclerosis, and the use of juvenile animals
re thought to play a role. Therefore, pre-clinical studies
eporting complete endothelialization of DES at 28 and 90
ays (10–12) in the porcine model failed to predict the
omplication of late stent thrombosis attributed to the lack
f strut coverage in man after bare-metal stent (BMS)
mplants (2,3). Relative to porcine coronary stent implants,
ndothelial regrowth in the rabbit occurs at a slower rate,
erhaps offering a more desirable model for assessing
e-endothelialization of DES (7).
Despite worldwide use of DES in millions of patients to
educe the risk for in-stent restenosis, little, however, is
nown of rates of endothelialization and recovery in com-
ercially available comparator stents. Therefore, the present
tudy was undertaken to assess re-endothelialization with
ocus on surface coverage and relevant mitogenic and
ntithrombotic properties among leading polymer-based
tent platforms.
Abbreviations
and Acronyms
DES  drug-eluting stent(s)
EES  everolimus-eluting
stent(s)
FDA  Food and Drug
Administration
PECAM  platelet-
endothelial cell adhesion
molecule
PES  paclitaxel-eluting
stent(s)
SEM  scanning electron
microscopy
SES  sirolimus-eluting
stent(s)
TM  thrombomodulin
VEGF  vascular
endothelial growth factor
ZES  zotarolimus-eluting
stent(s)
olymer-Based Comparator Drug-Eluting and MULTI-LINK Vision Ba
Table 1 Polymer-Based Comparator Drug-Eluting and MULTI-LIN
Stent Design
Strut Thickness
(mm) Polymer
Polymer T
(mm
Cypher 140 PEVAPBMA 12
Taxus Liberté 97 SIBBS 16
Endeavor 91 PC 5
XIENCE V 81 Fluoropolymer 7
MULTI-LINK Vision 81 — —Represents 14 days.
PC  phosphorylcholine; PEVAPBMA  polyethylene-co-vinyl acetate  poly n-butyl methacrylate; SIethods
abbit model of stent implantation. The study protocol
as reviewed and approved by the Institutional Animal
are and Research Committee, Jack H. Skirball Center for
ardiovascular Research (Orangeburg, New York), and
xperiments were conducted according to the National
nstitutes of Health Guide for the Care and Use of
aboratory Animals.
Anesthetized adult male New Zealand White rabbits
nderwent endothelial denudation of both iliac arteries
sing an angioplasty balloon catheter (3.0 10 mm, Abbott
ascular, Santa Clara, California). Subsequently, Cypher
Sirolimus, Cordis Corp., Johnson & Johnson, Miami,
lorida), Taxus Liberté (Paclitaxel, Boston Scientific,
atick, Massachusetts), Endeavor (Zotarolimus, Medtronic
ascular, Santa Rosa, California) and XIENCE V (Everoli-
us, Abbott Vascular) were deployed at a target stent-to-
rtery ratio of 1.3:1. Bare-metal cobalt-chromium MULTI-
INK (ML) Vision stents (Abbott Vascular) served as
ontrols (Table 1). Rabbits were anticoagulated with aspirin
40 mg/day) given orally 24 h before catheterization with
ontinued dosing throughout the in-life phase of the study,
hereas single dose intra-arterial heparin (150 IU/kg) was
dministered at the time of catheterization. After device
mplantation, post-procedural angiography was performed
o document vessel patency and the animals were allowed to
ecover.
tent harvest. The stents were harvested at 14 or 28 days
fter implantation. For evaluation of endothelial cover-
ge, the stented arteries were fixed in situ with 10%
eutral buffered formalin after perfusion with lactated
inger’s solution to remove blood. The samples were
urther fixed by immersion and then bisected longitudi-
ally with one half processed for scanning electron
icroscopy (SEM) and the opposite reserved for en face
mmunostaining of whole-mount vessels. The adjacent
roximal and distal nonstented segments served as a
ositive control for immunostaining.
Stents harvested for organoid culture or messenger ribo-
ucleic acid (mRNA) extraction were immediately removed
fter perfusion with lactated Ringer’s solution and placed in
ulture media or snap-frozen in liquid nitrogen, respectively,
ithout fixation.
tal Stent
ion Bare-Metal Stent
ss
Drug (Dose)
Total Dose
(g)
Release Kinetics
(28 Days)
Sirolimus (1.4 g/mm2) 135 68.4%
Paclitaxel (1.0 g/mm2) 85 10%
Zotarolimus (10 g/mm) 120 95%*
Everolimus (1.0 g/mm2) 56 80%
— — —re-Me
K Vis
hickne
)
.6
.3
.6BBS  poly(styrene-b-isobutylene-b-styrene).
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July 29, 2008:333–42 Endothelial Recovery of Drug-Eluting Stentsorphometric analysis of endothelial surface coverage.
omposites of serial en face SEM images acquired at low
ower (15 magnification) were digitally assembled to
rovide a complete view of the entire luminal stent surface.
he images were further enlarged (200 magnification),
llowing direct visualization of endothelial cells. The extent
f endothelial surface coverage above and between stent
truts was traced and measured by morphometry software
IPLab for Mac OS X, Scanalytics, Rockville, Maryland).
he results are expressed as a percentage of total surface area
bove or between struts or the total and percent area lacking
overage at each repeated crown along the longitudinal axis
rom proximal to distal orientation. Endothelial cells were
dentified as sheets of spindle or polygonal shaped mono-
ayers in close apposition, a distinguishing feature from
ther cell types in en face preparations (13,14). In contrast,
ntimal smooth muscle cells show elongated processes and
re generally stacked in disorganized or haphazard layers.
ther adherent cells present on stent surfaces include
latelets, characteristically 1 to 2 m in size with an
rregular discoid appearance, and inflammatory cells, which
re round in shape varying from 7 to 10 m in diameter
ith a ruffled surface. Struts uncovered by endothelium were
ompletely bare or contained thrombi consisting of focal
latelet and fibrin aggregates intermixed with red blood cells
nd inflammatory cells.
hole-mount en face immunostaining for platelet-
ndothelial cell adhesion molecule (PECAM)-1 and
hrombomodulin. Immunostaining of whole-mount spec-
mens was achieved by overnight incubation in an antibody
ocktail containing primary antibodies against PECAM-1
CD31, 1:20 dilution, Dako, Carpentaria, California) and
hrombomodulin (TM) (1:10, American Diagnostica,
tamford, Conneticut) at 4°C. Specific binding was visual-
zed using a secondary antibody cocktail consisting of
onkey-anti mouse Alexa Fluor 488 and donkey-antigoat
lexa Fluor 555 conjugate antibodies (1:200 dilution, In-
itrogen Corp., Carlsbad, California); TOTO-3 iodide
erved as a nuclear counterstain.
The extent of endothelial coverage based on a positive
eaction to PECAM-1 above and between stent struts was
isually semiquantified 100 magnification for each level of
truts and expressed as a mean percentage for the total area
bove and between stent struts for the entire stented surface.
hrombomodulin expression was assessed based on reaction
ntensity ranging from an absence to strong staining relative
o nonadjacent control segments. Final confocal images
ere acquired in a multitrack mode in which separate green
r red channels were scanned individually and then super-
mposed using the Zeiss LSM software, thereby eliminating
otential spectral overlap.
roduction of vascular endothelial growth factor
VEGF) from stents maintained in organoid culture. Se-
ect 14- and 28-day stents harvested for organoid culture
ere perfused in situ with lactated Ringer’s solution. Thetents were then immediately transferred to 3-ml serum-free Tulbecco modified Eagle medium and maintained at 37°C
n a humidified atmosphere of 5% CO2/95% air. After 48 h,
he conditioned medium was collected and total VEGF was
easured by enzyme-linked immunosorbent assay (EMD
ioscience Inc., San Diego, California). The kit recognizes
he diffusible VEGF-A isoforms of VEGF165 and
EGF121.
ibonucleic acid (RNA) extraction and reverse transcrip-
ion. The total RNA from competitor stents was isolated
sing TRI reagent (Applied Biosystems, Austin, Texas)
ollowed by cleaning with RNeasy mini kit (Qiagen, Valen-
ia, California). The isolated RNA was treated with RNase-
ree DNase I to remove genomic deoxyribonucleic acid
ccording to the Qiagen protocol. The total RNA samples
ere quantified using Nanodrop spectrophotometry (Wil-
ington, Delaware), and the quality of each RNA sample
as validated by measuring the A260/A280 ratio with
anodrop and RNA integrity number (RIN) with a RNA
ano 6000 Labchip kit and Agilent Bioanalyzer (Santa
lara, California).
First-strand complementary (c)DNA was synthesized
rom 1 g RNA using random hexamers and MultiScribe
everse Transcriptase in a final volume of 20 l according
o manufacturer’s instructions (Applied Biosystems). The
DNA products were diluted 25-fold with nuclease-free
ater before use.
uantitative real-time polymerase chain reaction
Q-PCR). Q-PCR was performed with SYBR green de-
ection reagent (SuperArray, Frederick, Maryland) by using
BI 7500 fast real time PCR system (Applied Biosystems,
oster City, California). Each reaction contained 1l
DNA template. All samples were performed in duplicate
r triplicate conditions with the thermal cycling profile
onsisting of three stages: 95°C for 10 min, 40 cycles of 15 s
t 95°C and 60°C for 1 min, followed by a dissociation curve
rogram.
Gene-specific primers were designed using Primer Ex-
ress 3.0 software (Applied Biosystems). Primer specificity
as confirmed by the dissociation curve, which contained
nly a single peak.
Primers for PCR (5’-3’):
18S forward: GCA GCC AGG AAT AAT GGA ACA G
18S backward: GCC TCA GTT CCG AAA ACC AA
VEGF forward: CCA TGG CAG AAG AAG GAG ACA
VEGF backward: CGC CGG TAG ACT TCC ATG A
The PCR amplification efficiencies and the threshold
ycle (Ct) value of each gene were determined by instru-
ent’s software. Relative expression of mRNA was calcu-
ated using the delta-delta Ct method, which involves
omparing Ct values between tested samples. The internal
eference gene of 18S rRNA was used to normalize the
mount of RNA from all samples based on its consistent
xpression in rabbits relative to the housekeeping genes,
lyceraldehyde 3-phosphate dehydrogenase or -actin (15).
he relative expression of target genes was presented as fold
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Endothelial Recovery of Drug-Eluting Stents July 29, 2008:333–42hange with the control bare-metal ML Vision stent as
alibrator (ML Vision equal to 1).
tatistical analysis. Data are expressed as means  SD.
ultiple group comparisons were achieved using a 1-way
nalysis of variance (ANOVA). If the variance ratio test (F
est) was significant, post hoc analysis of differences
etween-groups means were made using the Dunnett test.
he BMS group was used as a control and compared with
arious DES in Dunnett tests. A p value of 0.05 was
onsidered statistically significant.
esults
ndothelial coverage of ML Vision control stents at
arious intervals. Preliminary studies determining the
ime course of re-endothelialization were performed in 22
abbit iliac arteries with bare-metal ML Vision stents
eployed for 3, 7, 14, and 28 days. The stents were analyzed
y methods of scanning and confocal microscopy, as de-
cribed earlier. Re-endothelialization by SEM showed
9.9  7.4% of strut surfaces covered at 14 days, with com-
lete overlay by 28 days (7). The percentage of PECAM-
–positive endothelial cells over struts followed similar
rends with 76.6  34.2% of covered strut surfaces at 14
ays and 95% by 28 days. Based on this preliminary
nalysis, re-endothelialization of comparator DES and
MS were studied at 14 and 28 days.
omparator DES and ML Vision control implants. The
xtent of endothelial regrowth examined by SEM and dual
mmunostaining against PECAM-1 and TM was assessed
n a total of 96 bilateral DES and BMS (4 to 6 stents per
roup) implanted in 48 rabbits for 14 and 28 days. In
eparate experiments, an additional 80 DES and BMS
4 per group) were implanted in 40 rabbits at similar time
oints for analysis of VEGF release in organoid culture and
RNA expression. The stent-to-artery ratios at the time of
mplant were similar among groups (SES  1.4  0.17,
ES  1.4  0.30, ZES  1.2  0.49, EES  1.3  0.05,
nd ML Vision control stent  1.2  0.12, p  NS). All
nimals survived the in-life phase of the study, and there
ere no complications of catheterization. All stents were
ngiographically patent at the time of euthanasia without
vidence of migration or aneurysm formation.
ndothelial coverage by SEM. At 14 days, re-endothe-
ialization above struts was variable among comparator stents
ith significantly greater coverage in EES (64.0  27.5%),
ollowed by ZES (30.2 14.2%), PES (26.8 15.8%), and
ES (6.4  4.2%), versus EES (p  0.003) and ML Vision
ontrol stents (p  0.0001) (Figs. 1A and 2). In contrast,
reas between struts showed 70% of surface area coverage
or all DES, which was most complete in EES (90.4 
2.4%) compared with ZES (80.6  9.7%), PES (74.1 
6.6%), or SES (72.1  9.6%) with borderline significance
etween groups (p  0.08). Struts lacking endothelial
overage, as in SES and PES, generally showed focal
ggregates of platelets and inflammatory cells, including siant cells. To a limited degree, adherent inflammatory cells
nd platelets were also found on endothelial surfaces, but no
ifferences were noted between comparator DES (data not
hown).
At 28 days, endothelial coverage above struts was 60%
ith borderline differences among comparator SES and
ES versus ML Vision controls (Figs. 1B and 3). Areas
bove struts lacking endothelial cells showed persistent
nflammatory cells and platelets/fibrin on bare surfaces.
nflammatory cells were also present in EES and ZES,
owever, mostly on uncovered stent struts. In comparator
ES (in particular in SES and PES), rare macrophages
ere seen in intercellular spaces created by poorly formed
ell–cell contacts.
otal and distribution of uncovered struts among com-
arator DES. Notable differences in total surface area and
ercent distribution of uncovered struts along the longitu-
inal crown structures from proximal to distal were found
mong 14- and 28-day comparator DES and ML Vision
ontrol stents (Fig. 4). The least area of uncovered struts
as observed in ML Vision control stents (0.85  0.90
m2 and 0.12  0.12 mm2) at 14 and 28 days, respectively.
mong 14-day DES, the area of uncovered struts was least
n EES, representing an approximate 2- to 3-fold increase
ver ML Vision controls (Fig. 4A). In contrast, there was at
east a 5-fold increase in the area of uncovered struts in SES,
ES, and ZES, reaching statistical significance over ML
ision (p 0.0001). At 28 days, the total area of uncovered
Figure 1 Quantitative Analysis of Endothelial
Coverage Based on Morphometric Analysis
Bar graphs showing the quantitative analysis of endothelial coverage above
(left) and between struts (right) at 14 (A) and 28 days (B). Comparator drug-
eluting stents (DES) and bare-metal MULTI-LINK Vision control stents (BMS)
based on morphometric analysis of images from scanning electron microscopy
(SEM). EES  everolimus-eluting stents; PES  paclitaxel-eluting stents; SES
 sirolimus-eluting stents; ZES  zotorolimus-eluting stents.truts decreased approximately 50% in all DES with a
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July 29, 2008:333–42 Endothelial Recovery of Drug-Eluting Stentsersistent increase in uncovered struts in PES and SES over
L Vision controls, with the latter approaching only
orderline significance.
Along the longitudinal axis, the percentage of uncovered
rea at each strut was more prevalent in the middle regions
f all stents, producing a bell-shaped curve, as the extreme
nds of the stents were generally well covered except for
ES, which showed a general lack of coverage (Fig. 4B).
his trend remained apparent at 28 days, although the
ercent area of uncovered struts was markedly less, specif-
cally for SES, PES, and ZES; however, uncovered struts in
he mid portions of all DES remain poor while the
ercentage of uncovered struts in ML Vision control stents
as minimal (Fig. 4B).
ndothelial monolayer integrity by PECAM-1 immu-
ostaining. Among DES, areas of endothelial cells with
ECAM-1 localized to cell-to-cell contact sites above struts
ere significantly greater for EES (45.9  35.6), followed
y PES (21.3  11.8), ZES (7.4  10.2), and SES (5.8 
.8), whereas 14-day ML Vision control stents showed the
argest extent of coverage (55.89 30.2) (Figs. 5A and 6A).
ercentages of cells expressing PECAM-1 between struts
ere similar in EES, PES, and control ML Vision stents,
hich were relatively higher than SES and ZES (p 
.008). The trends in PECAM-1 staining were similar to
EM findings, although the percent coverage was consis-
Figure 2 Scanning Electron Micrographs of 14-Day Comparator
The upper panels show corresponding radiographic images of each stent. The lumens
Among DES, there is less endothelial cell surface coverage in SES and PES stents co
tion (200) from proximal and distal regions showing bare struts, surface thrombi, inflently less by PECAM-1, suggesting an overall decreased Vaturation of junctional complexes within stents. At 28
ays, PECAM-1 staining above struts was similar for EES
67.5  35.8) and ZES (64.3  35.8), but less than ML
ision controls (88.1  22.1), whereas in PES and SES,
reas positive for PECAM-1 were50% (Figs. 5B and 6B).
here were no significant differences among DES groups
etween stent struts at this time point (Fig. 5B).
hrombomodulin immunostaining. In nonstented con-
rol segments, TM was diffusely distributed in the cyto-
lasm with variable expression localized at intercellular
oundaries with PECAM-1 (Figs. 6A2 and 6A3). Despite
arying degrees of endothelial coverage at 14 and 28 days,
M was absent or only weakly expressed (Fig. 6B), irre-
pective of DES. In contrast, endothelial staining for TM
howed mild to moderate intensity in ML Vision control
tents at 14 and 28 days, respectively, but did not achieve
he intensity of control nonstented segments.
EGF release from stented arterial segments in organoid
ulture and mRNA levels by quantitative PCR. Analysis
f conditioned media collected from 14-day stented arterial
egments maintained in organoid culture over 48 h showed
3- to 4-fold increase in VEGF release in SES, PES, and
ES relative to EES and ML Vision control stents (Fig. 7).
he persistent release of VEGF in select DES was also
bserved at 28 days with similar trends noted. The Q-PCR
nalysis of 14-day stents revealed a parallel increase of
and BMS Controls
early patent and struts are easily discerned underneath a thin neointimal surface.
with ZES and EES. The panel insets are representative images at higher magnifica-
tory cells, and endothelial cells. Abbreviations as in Figure 1.DES
are cl
mpared
ammaEGF mRNA levels consistent with those DES with
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Endothelial Recovery of Drug-Eluting Stents July 29, 2008:333–42igher amounts of VEGF. At 28 days, however, VEGF
RNA transcription was equivalent among all stents.
In separate experiments of subconfluent human umbilical
ein endothelial cells treated with paclitaxel or sirolimus
IC50 range), increased VEGF mRNA production was
ound at 96 h over baseline, whereas control cells treated
ith saline showed a reciprocal decrease (data not shown).
iscussion
he present study marks the first comparator analysis of
ndothelial surface coverage in various polymeric DES
sing a well-characterized rabbit model of iliofemoral artery
tenting (16). Endothelial coverage between struts occurred
ore rapidly than above struts, where differences in the
arious stent platforms were most notable at 14 days. In the
abbit, EES and ML Vision control stents showed a greater
xtent of endothelial coverage above struts relative to the
urrent generation of FDA-approved stents (i.e., ZES,
ES, and SES) at 14 days but not at 28 days. Further, there
as reduced expression of PECAM-1 at cell-to-cell con-
acts evidenced by discontinuous or lack of immunostaining
n 14-day SES, PES, and ZES, compared with EES and
L Vision control stents. This finding persisted at 28 days
espite more apparent endothelial coverage by SEM anal-
sis, suggesting delayed maturation or increased turnover of
Figure 3 Scanning Electron Micrographs of 28-Day Comparator
The upper panels show corresponding radiographic images of each stent. The lum
14-day stents. Overall endothelial coverage is near complete in all DES although it
insets are at higher magnification (200) from the proximal and distal regions and
lial cells. Abbreviations as in Figure 1.ndothelial cells. Stent surfaces showed minimal endothelial dxpression of TM in all DES relative to ML Vision control
tents, whereas it remained strongly positive in adjacent
onstented segments. Increased VEGF secretion and
RNA levels correlated with delayed endothelialization in
4-day SES, PES, and ZES in contrast to EES and ML
ision control stents, where endothelial coverage was more
omplete. The increased VEGF release persisted at 28 days,
urther providing evidence of a transitional immature endo-
helial surface in select DES.
actors responsible for delayed endothelial regrowth in
ES. Intuitively, the disparity of endothelial coverage
bove and between struts partially arises from physical
ontact, where strut surfaces provide greater injury and drug
xposure, whereas inter-struts areas are exposed to less
njury and lower concentrations of drug (17). Consistent
ith BMS, endothelial regrowth seems to arise from intact
ndothelium adjacent to the injured site as it divides and
igrates to reline the arterial surface (18). This finding is
onsistent in the present study, in which endothelial cover-
ge was generally more complete at the extreme proximal
nd distal regions of the stent versus the middle segments.
Regional differences in blood flow dictated by varying
tent configurations and altered shear stresses are capable of
mpacting endothelial growth (19,20). Specifically, flow
isturbances caused by increased strut thickness are a likely
and BMS Controls
e patent and struts are less discernable under a thicker neointima relative to
ins poor above struts in PES and SES compared with ZES and EES. The panel
persistent uncovered struts, surface thrombi, inflammatory cells, and endothe-DES
ens ar
rema
showeterrent of endothelial coverage. In a seminal study under
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July 29, 2008:333–42 Endothelial Recovery of Drug-Eluting Stentsow and shear conditions similar to those found in arteries,
imon et al. (21) found the extent of endothelial coverage is
ependent on object thickness. After 24 h, endothelial cell
Figure 4 Morphometric Analysis of Uncovered Strut Area (mm2
The summary table (A) shows the total area (mm2) of uncovered struts was significan
Panel B represents a series of line graphs representing the quantitative distribution o
mal to distal. Uncovered struts were more prevalent in the middle regions of most ste
stent length. Analysis of 28-day stents shows a persistent lack of strut coverage in th
Figure 5 Quantitative Analysis of Endothelial Coverage
Based on Immunostaining Against PECAM-1
Bar graphs showing the quantitative analysis of endothelial coverage above
(left) and between struts (right) at 14 (A) and 28 days (B). Comparator DES
and BMS based on immunostaining against platelet-endothelial cell adhesion
molecule (PECAM)-1. Abbreviations as in Figure 1.toverage and maximum migration distance significantly
ecreased over objects 75 m and was nonexistent at 250
m. These data support previous clinical studies in which
educed arterial injury and restenosis are associated with
hinner struts (22–24). Strut/polymer thickness in the
resent study was least in stents with greater endothelial
overage: EES (89 m) and ZES (96 m) compared with
ES (113 m) and SES (153 m), where endothelial
overage was uniformly poor (Table 1).
The drug dose/polymer combination and release proper-
ies may also affect endothelial cell proliferation and migra-
ion. Pharmacokinetic profiles (in vivo) for sirolimus, SES,
nd everolimus, EES, show 68.4%, and 79.5% of the total
rug released at 28 days, respectively (11,25), whereas the
ajority (95%) of zotarolimus, ZES, is released by 14 days
26). Therefore, comparative release rates alone do not
xplain the relative increased endothelial coverage with
ES, which may be secondary to a lower loading dose
ogether with the rapid release rate. In contrast, only 10% of
aclitaxel (slow-release PES) is released by 28 days, where
ocal concentrations of this cytotoxic drug achieve therapeu-
ic doses capable of inhibiting endothelial proliferation and
igration and inducing apoptosis as well (27,28).
ndothelial cell monolayer integrity and PECAM-1. In
he present study, we examined the expression of the
ndothelial antigen PECAM-1, a molecule proven critical
ong Comparator DES and BMS Control Stents
ater in SES, PES, and ZES compared to MULTI-LINK Vision, especially at 14 days.
ered struts at each repeat crowns along the longitudinal axis of the stent from proxi-
cept for SES at 14 days where uncovered struts were prominent along the entire
egment of SES and PES compared with BMS. Abbreviations as in Figure 1.) Am
tly gre
f uncov
nts, ex
e midso endothelial homeostasis. PECAM-1 is a transmembrane
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Endothelial Recovery of Drug-Eluting Stents July 29, 2008:333–42lycoprotein concentrated in broad areas of cell-to-cell
ontact where homophilic interactions with PECAM-1 of
eighboring endothelial cells occur (29). Endothelial cells
orm poor cell junctions during processes such as cell growth
nd migration, displaying a loss of PECAM-1 immuno-
taining at endothelial margins (30,31). The extent of
ndothelial regrowth assessed by en face immunostaining
gainst PECAM-1 followed similar trends as seen by SEM
nalysis, although area coverage was notably less in the
ormer. In particular, PECAM-1 expression over struts in
4- and 28-day SES and PES was generally poor, suggest-
ng an inhibition of endothelial cell migration and prolifer-
tion, endothelial injury, and/or increased cell turnover.
The expression of TM, a physiologically relevant regula-
or of platelets and coagulation, was also examined because
he loss of TM function causes spontaneous thrombosis
n the arterial and venous circulation (32). Overall staining
or TM was absent or only weakly expressed in 14- and
8-day DES, and was even reduced in ML Vision control
tents compared with nonstented segments. This finding
ay be of clinical importance because dysfunctional endo-
helium combined with a lack of endothelial coverage may
lso play a role in late stent thrombosis. No animal or
uman pathologic study to date has examined the expres-
ion of proteins critical to endothelial homeostasis in stents.
Figure 6 Dual Immunofluorescence for PECAM-1 and TM
Dual immunofluorescence for PECAM-1 and thrombomodulin (TM) in whole mount
shows strong cell-cell border localization of PECAM-1 while panel A2 shows diffuse
(A3) shows minimal fluorophore overlap (yellow); TOTO-3 (blue) was used as a nu
(bottom row) merged confocal images of 14-day stents dual stained for PECAM-1
for each stent type, with more uniform expression above struts in EES and BMS. S
Thrombomodulin expression was weak or absent in all DES, while mild to moderateduced expression of TM in DES suggests a switch to a dore prothrombogenic state similar to that reported in early
ein grafts in the rabbit (33,34). Moreover, the inability of
ES to provide an antithrombogenic surface parallels in
itro studies in which endothelial cells treated with pacli-
axel or sirolimus show increased tissue factor mRNA and
rotein expression (35,36). Both rapamycin and paclitaxel
lso selectively enhance the expression of plasminogen-
ctivator inhibitor type I, a potent inhibitor of fibrinolysis
nd mediator of acute thrombosis (37).
ntegrity of the surface endothelium in DES: mainte-
ance by VEGF. Overexpression of VEGF accelerates
ndothelial repair and inhibits neointimal formation after
rterial injury (38,39). Increased levels of VEGF correlate
ith regenerating versus quiescent endothelial cells as
EGF message and protein expression peak early after
rterial injury and then diminish with greater healing
40,41). In our study, secreted VEGF and mRNA levels
ere highest in SES, PES, and ZES, stents with poorly
ndothelialized surfaces at 14 days. The persistent produc-
ion of VEGF in selected DES seems to be a function of
ncomplete endothelialization rather than a direct effect of
he drug as rapamycin, for example is reported to partially
ownregulate VEGF in tumors via mTORC2 (42). Al-
hough secreted VEGF correlated with increased mRNA
evels at 14 days, stents harvested at 28 days showed
l non-stented (A1 to A3) and stented (B) arterial segments. Panel A1, control
ing for TM with relatively weak staining at the cell periphery. The merged panel
counterstain. Panel B represents low (upper row) and higher magnification
) and TM (red). The extent of PECAM-1 positive endothelial cells was variable
with poor expression for PECAM-1 were more frequent in SES, PES, and ZES.
ing was noted in BMS. Abbreviations as in Figures 1 and 5.contro
stain
clear
(green
truts
e stainiscordant VEGF protein and mRNA levels where secreted
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July 29, 2008:333–42 Endothelial Recovery of Drug-Eluting StentsEGF from select DES was found independent of tran-
criptional activation. The regulatory pathways of VEGF
re undoubtedly complex because differential rates of heal-
ng of various DES may effect post-translational processes
nvolving the proteolytic release of matrix-bound and
eceptor-bound VEGF isoforms (43).
linical implications and perspectives. Several factors are
ssociated with an increased risk of stent thrombosis,
ncluding the procedure itself (stent malapposition and/or
nderexpansion, number of implanted stents, stent length,
ersistent slow coronary blood flow, and dissections), pa-
ient and lesion characteristics, stent design, and discontin-
ation of antiplatelet drugs (44). It is important to empha-
ize that similar factors have been implicated in late stent
hrombosis of BMS (45). Nonetheless, the apparent off-
abel use of DES has given rise to the ongoing debate of
ncreased risk of late stent thrombosis in these devices (46).
Our results support an increased late thrombotic risk
ssociated with DES relative to BMS caused by inadequate
ndothelial coverage over stent struts. The restoration of
ndothelial function within the stent may be further im-
aired because of an underlying dysfunctional endothelium
n symptomatic plaques. Moving beyond the exuberance of
uring restenosis, attention should focus on stent strut
overage rather than late loss alone because the persistent
ack of coverage as reported in recent clinical (47) and
utopsy (3) studies may serve as a nidus for thrombosis.
mproved stent designs with thinner struts, more biocom-
atible polymers, or elimination of polymers with optimized
rug elution profiles will likely have a profound impact on
Figure 7 Measurement of VEGF Production and mRNA
Levels by Q-PCR at 14- and 28-Day Stent Implants
(A) Vascular endothelial growth factor (VEGF) secretion from stents (harvested
at 14 and 28 days) maintained in organoid culture over 48 h showed a signifi-
cant increase in SES, PES, and ZES relative to EES and BMS. (B) Concordant
quantitative polymerase chain reaction (Q-PCR) analysis of VEGF messenger
ribonucleic acid (mRNA) levels matches with DES showing higher released
amounts of VEGF at 14 days.ndothelial coverage, but these are slow to reach approvalecause they require extensive pre-clinical study and large
andomized clinical trials powered for safety end points.
he selection of appropriate animal models, porcine versus
abbit, may also be important for the study of endothelial
egeneration.
tudy limitations. The appropriate bare-metal control
tents matched for the various DES (SES, PES, and ZES)
ere unavailable, thus preventing the assessment of stent
onfigurations on re-endothelialization. Moreover, balloon
enudation was performed before stenting, which can in-
uence the degree of endothelial coverage. In the clinical
etting, stent deployment without antecedent balloon denu-
ation leaves more endothelium intact, lowering the re-
uirement for endothelial proliferation and migration. Be-
ause all DES were tested in the iliac arteries, these results
ay not be directly applicable to the coronary vascular bed
ecause of differences in shear rates.
The study of normal arteries also may not adequately
epresent biological responses of human atherosclerotic
rteries treated with DES because pre-existing inflamma-
ion in atherosclerotic arteries may further delay healing.
he impact of platelet interactions on restoration of endo-
helial integrity was also not addressed, as thienopyridines
ere not administered. Nonetheless, our rabbit model
ould have predicted the likelihood of late stent throm-
osis with Cypher and Taxus stents. Conversely our data
egarding ZES and EES falls short of predicting safety in
egard to late stent thrombosis, which requires confirma-
ion in long-term clinical trials in a large number of
atients. Notably, all DES examined showed a lack of
ndothelial anticoagulant function independent of sur-
ace coverage.
onclusions
 disparity in arterial healing involving re-endothelialization of
arious polymeric DES in the rabbit was observed at 14
ays. Endothelial coverage among DES was less discernable
t 28 days, the traditional time point for analysis of stents in
nimals, likely caused by accelerated rates of arterial healing
elative to humans. Significantly less endothelial strut cov-
rage at 14 days was more apparent in earlier stent designs
oaded with SES or PES relative to the more recent EES or
ES.
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